News Articles for Orthocell

Our board moves wrap includes Roger Port, Lars Lidgren, Leslie Wise, Peter Harold, Craig Jones, Derek La Ferla, Dean Hildebrand, Harry Miller, Lee Tamplin, and David Franks.

Our board moves wrap includes Gregory Bittar, Josh Hunt, Ben Smith, John Van Der Wielen, and Stewart Washer.

John Van Der Wielen will chair Murdoch-based biotechnology company Orthocell as it prepares to scale up manufacturing with a new facility.

Three new local funds proposing to focus on early-stage investment are raising expectations.

Our board moves wrap includes Andrew Haythorpe, Gavin Ball, Nicholas Revell, Ravi Thadhani, Arnaud Breuillac, Sarah Ryan, Christopher Haynes, Peter Huljich, Richard Monti, and Jerry Monzu.

Our board moves wrap includes Chris Radin, Sheila Khama, Stirling Ross, Gerry Kaczmarek, Tony Kiernan, Derek Humphry, Dale Richards, Nerida Schmidt, Patricia Farr, Simon Robertson, Susan Park, Peter Webse, ChongTao Xu, Andrew Taplin, Carol Marinkovich, Rowan Harland, Arron Canicais, David Lim, Andrew Woskett, Benjamin Donovan, and Shaun Menezes.

Helping patients by solving an unmet medical need whilst creating jobs and generating a revenue stream might seem like the ultimate win-win-win for a healthcare professional. However, getting a good idea to market means embarking on a long and winding road to commercialisation. Enter the Australian Clinical Entrepreneur Program launched recently in Perth.

Perth-based Orthocell has struck a 25-year licensing and distribution agreement valued at $23.1 million with a major dental implant company.

WA has many advantages in terms of hosting a thriving medical research and innovation ecosystem.

The Perron Institute is kicking commercial goals, courtesy of big sales royalties and a planned ASX listing.

Perth-based biotherapeutic company Orthocell has received US approval for the use of its dental bone and tissue regeneration platform.

Our board moves wrap includes John McGlue, Andrew Teo, Leslie Wise, Greg Clark, Kathryn Davies, Bruce Griffin, and Rod Jones.

SPECIAL REPORT: As markets struggle under the pressure of the COVID-19 pandemic, the medtech industry has found itself with an unparalleled, if challenging, opportunity.

Matt Callahan has re-joined the board of Botanix Pharmaceuticals as an executive director following the decision by Robert Towner to step down as non-executive director.

Bio-therapeutic company Orthocell has received commitments to raise $13 million from a share placement and up to a further $5 million from a share purchase plan, primarily to accelerate the commercialisation of its CelGro flagship product.

Our daily board moves wrap includes Matt Callahan, Simon Paull, Alan Armstrong, David Rich, and Patrick Glovac.

Orthocell has capitalised on a sustained rally in its share price to raise $10.6 million via a share placement at 40 cents per share.

Shares in Perth biotech Orthocell more than quadrupled in value today after the company released positive results from a trial of its nerve regeneration product.

On 12 January 2018, Valmec completed the issue of 22,522,083 fully paid ordinary shares in the capital of the Company (Option Shares) upon the exercise of 22,522,083 listed options (ASX:VMXO) with

Perth-based Orthocell has raised $4 million to fund ongoing development of its regenerative medicine products.

Regenerative medicine group Orthocell has topped Techboard's first startup and tech company ranking for the year, following news it had been granted a US patent for its ‘cell factory' product.

Shares in Perth-based Orthocell have soared after the tissue regeneration company was granted a patent for its "cell factory" technology in the United States.

Gleneagle Gold will make a second attempt at a reverse takeover with plans to buy a local unlisted medical cannabis company in a deal worth about $8 million.

A surge in the number of backdoor listings was one of the few positives on the stock market in 2014, and two new deals for technology companies show there is more to come.

Shares in Perth-based biotechnology company Orthocell have risen slightly on the back of it striking a partnership with leading Swedish medical technology company Bonesupport.

WA biotechs are drowning in a sea of red as yet more negative results are reported.

Perth-based explorer Tian Poh Resources has launched an initial public offering to raise up to $6 million, to fund exploration and development of its Mongolian assets.

FEATURE: The June quarter presented a broad range of transactions for corporate players, however a noticeable lack of direction remains.

Perth-based biotech firm Orthocell has confirmed it intends to list on the ASX after outlining plans for an $8 million initial public offering.

Biotech player Orthocell has appointed two financial advisory firms to seek out investors as part of the company's plans to go public.

FEATURE: The state's biotechnology sector is heating up as investors look for the next wave of investment opportunities amid waning resources investment.